Data Readout

Vedanta's VE303 Phase 3 cleared its first futility check; a second test looms

RESTORATiVE303's data monitoring committee let the C. diff trial continue unmodified in April, and a second prespecified interim look is due later in 2026, well before the trial's 2027 completion.

By AppliedXLJuly 13, 2026Trial NCT06237452

Executive Summary

Vedanta Biosciences' pivotal C. difficile trial passed an interim safety and efficacy check, with an independent committee recommending the study continue unchanged.
The finding indicates the accumulating data have not fallen below the threshold that would have triggered a stop or redesign, keeping the trial's path toward a regulatory filing intact.
A second interim look is coming later this year, ahead of the trial's own primary completion date next year, giving the sponsor another data-backed checkpoint before the pivotal readout.
No Phase 3 program shares VE303's defined bacterial-consortium mechanism, so the trial's result will land without a direct same-mechanism comparator, even as several other modalities work the same recurrence-prevention problem.

The checkpoint

Vedanta Biosciences, Inc. disclosed on April 2, 2026 that the data monitoring committee overseeing RESTORATiVE303, its pivotal Phase 3 trial of VE303 for prevention of recurrent Clostridioides difficile infection, completed a first prespecified interim analysis and recommended the trial continue as planned. The committee's unblinded review found that efficacy to date exceeded the prespecified futility threshold and that no new safety signals had emerged. The analysis triggered once half of the planned enrollment of patients with at least one prior CDI recurrence reached the Week 8 primary efficacy timepoint. A second prespecified interim analysis is planned for earlier in the second half of 2026, ahead of full enrollment completion targeted for the same period. Vedanta

Probability of Success

Endpoint Met89%

Completes52%

Clinical Significance73%

Regulatory80%

The design and the bar

RESTORATiVE303 is a randomized, double-blind, placebo-controlled Phase 3 trial (NCT06237452) testing whether an 14-day oral course of VE303, a defined eight-strain bacterial consortium delivered as a live biotherapeutic product, reduces CDI recurrence at Week 8 versus placebo in patients randomized 2:1 following antibiotic treatment for a prior episode. The trial targets 852 patients across more than 150 sites in roughly 20 countries, including the United States, Spain, Canada and Italy, and is registered to complete primary analysis by June 1, 2027. Vedanta has said the trial is intended to form the basis for a Biologics License Application with the FDA. In the earlier Phase 2 CONSORTiUM study, high-dose VE303 produced a 30.5% adjusted absolute risk reduction in CDI recurrence versus placebo, described by the sponsor as an over 80% reduction in the odds of recurrence; the Phase 3 primary endpoint, CDI recurrence rate at Week 8, is the bar this trial must clear to reproduce that signal at scale. NCT06237452+1

Operational read

The trial's registered enrollment target has held flat at 852 patients with no growth or cut recorded against the anticipated figure, a routine signal rather than a change in trial size. Protocol history shows only an initial study registration and a status change from Not-yet-recruiting to Recruiting in May 2024, with no primary-endpoint amendments and no completion-date change recorded. That protocol stability, combined with a data-backed continuation recommendation rather than a lapsed or overdue checkpoint, points to a trial executing on its original design rather than one showing distress. NCT06237452

The competitive field

No other Phase 3 program in recurrent CDI prevention shares VE303's defined bacterial-consortium mechanism; other late-stage modality precedents in the indication include fecal microbiota-derived products and monoclonal-antibody and small-molecule approaches that address the same recurrence problem through broader microbiome restoration, toxin neutralization, or antibiotic mechanisms rather than a defined, rationally selected strain set. With no validated mechanism in this class yet established through a completed Phase 3 readout for VE303 itself, a Week 8 recurrence-rate result that approaches the Phase 2 risk-reduction magnitude, sustained through full enrollment, would be the result that most clearly extends the earlier signal into pivotal-scale evidence.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.